Details of the Drug

General Information of Drug (ID: DMMZS2T)

Drug Name
177-Lu-oxodotreotide
Indication
Disease Entry ICD 11 Status REF
Neuroendocrine cancer 2B72.1 Phase 3 [1]
Drug Type
Small molecular drug
Cross-matching ID
TTD ID
DQP87H

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor (SSTR) TTOMNR9 NOUNIPROTAC Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01842165) 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (LUMEN). U.S. National Institutes of Health.
2 Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.